QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 beyondspring-q2-eps-004-up-from-010-yoy

BeyondSpring (NASDAQ:BYSI) reported quarterly losses of $(0.04) per share. This is a 60 percent increase over losses of $(0.10)...

 beyondspring-drug-triggers-immune-response-in-patients-who-failed-prior-cancer-immunotherapy

BeyondSpring Inc. (NASDAQ:BYSI) today announced publication of a human clinical study in Med (Cell Press) demonstrating that Pl...

 beyondspring-presents-interim-phase-2-data-on-303-study-with-financial-support-from-mercks-investigator-studies-program-and-provision-of-study-drug-at-2025-asco-annual-meeting

Median PFS at 6.8 months, Disease Control Rate of 77.3%, 15 months OS% at 78% in Metastatic NSCLC Patients after Progression on...

 update-beyondspring-q1-eps-006-down-from-005-yoy

BeyondSpring (NASDAQ:BYSI) reported quarterly losses of $(0.06) per share. This is a 20 percent decrease over losses of $(0.05)...

 beyondspring-presented-final-data-on-dublin-3-study-2l3l-egfr-wild-type-nsclc-focusing-on-safety-outcomes-at-european-society-for-medical-oncology

Docetaxel remains the standard of care for patients with 2L/3L NSCLC without targetable alterations despite severe neutropenia ...

 beyondspring-presents-final-phase-3-results-for-plinabulin-in-2l3l-nsclc-at-islac-2024-with-concurrent-publication-in-the-lancet-respiratory-medicine

Statistically Significant and Clinically Meaningful Efficacy Data with Favorable Benefit/Risk ratio from DUBLIN-3 Phase 3 Stu...

 beyondspring-reports-fy23-loss-per-share-of-054-vs-085-last-year

As of December 31, 2023, the Company had cash, cash equivalents, restricted cash, and short-term investments of $17.9 million. ...

 beyondspring-doses-first-patient-with-pembrolizumab-plinabulin-plus-etoposideplatinum-in-a-phase-2-investigator-initiated-study-of-first-line-extensive-stage-small-cell-lung-cancer

Current treatment for first-line ES-SCLC includes EP and EP plus PD-L1 antibodies. Although the objective response rate (ORR) i...

 why-united-natural-foods-shares-are-trading-lower-by-15-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Shares of United Natural Foods, Inc. (NYSE: UNFI) fell sharply during Wednesday’s session following second-quarter results.

 why-sophia-genetics-shares-are-trading-lower-by-19-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of SOPHiA GENETICS SA (NASDAQ: SOPH) fell sharply during Tuesday’s session after the company reported worse than expect...

 beyondspring-regains-compliance-with-nasdaq-minimum-bid-price-and-periodic-filing-requirements

BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a global clinical-stage biopharmaceutical co...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION